Regulatory Processes for Rare Disease Drugs in the United States and European Union
Flexibilities and Collaborative Opportunities
Description
Rare diseases, such as sickle cell disease and thalassemia, affect up to 30 million people in the United States and at least 300 million across the globe.
I have a question about the book:
‘Regulatory Processes for Rare Disease Drugs in the United States and European Union - National Academies of Sciences, Engineering, Health and Medicine Division, Board on Health Sciences Policy, Committee on Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European’.
Fill in the form below.
We will respond as fast as possible.
We value your privacy
We use cookies to measure traffic, improve Boekstra and let Google tailor ads to your interests. You can keep using the site either way — even if you decline. More info
